baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

JP Morgan Put 440 VRTX 17.04.2025/ DE000JT7L9M1 /

1/24/2025 8:44:19 AM	Chg.-0.50	Bid7:16:58 PM	Ask7:16:58 PM	Underlying	Strike price	Expiration date	Option type
2.56EUR	-16.34%	2.55 Bid Size: 20,000	2.60 Ask Size: 20,000	Vertex Pharmaceutica...	440.00 USD	4/17/2025	Put

GlobeNewswire 8/13/2024 Entrada Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire 8/9/2024 ProKidney Reports Business Updates and Second Quarter 2024 Financial Results

GlobeNewswire 8/7/2024 Editas Medicine Announces Second Quarter 2024 Results and Business Updates

GlobeNewswire 8/5/2024 Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

GlobeNewswire 8/5/2024 CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Newsfile Corp 7/17/2024 Analysts Hunt for Undervalued Biotech Stocks

Newsfile Corp 7/11/2024 Biopharma Stocks Transformative Innovation for the Future of Health

GlobeNewswire 7/9/2024 Payscale Expands Data & Technology Resources, Powering Decision-Focused Compensation Management

GlobeNewswire 7/9/2024 Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

GlobeNewswire 6/28/2024 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...

GlobeNewswire 6/10/2024 Centessa Pharmaceuticals Strengthens Executive Leadership with Appointment of John Crowley CPA, as C...

GlobeNewswire 5/29/2024 CRISPR Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 5/23/2024 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 5/15/2024 Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/9/2024 CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

GlobeNewswire 5/8/2024 CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire 5/8/2024 CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...

GlobeNewswire 5/8/2024 Editas Medicine Announces First Quarter 2024 Results and Business Updates

GlobeNewswire 5/7/2024 Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire 4/30/2024 American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...

GlobeNewswire 4/27/2024 SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN

GlobeNewswire 4/25/2024 American Kidney Fund Launches National Kidney Health Equity Media Campaign

GlobeNewswire 4/22/2024 TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...

GlobeNewswire 4/22/2024 CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...

GlobeNewswire 4/22/2024 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN

JP Morgan Put 440 VRTX 17.04.2025/ DE000JT7L9M1 /

If you wish to receive reply to your feedback, please provide your email address.